Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or
bacterial infection and induce host innate immune responses. The RLRs family comprises …

Biliary tract cancers are an uncommon set of gastrointestinal malignancies that are
associated with high morbidity and mortality rates. Most patients present with incurable …

The incidence of cholangiocarcinoma (CCA) has been increasing over the past few years.
Although there are surgery, chemotherapy and other conventional treatment methods, the …

Even though the discovery of immune checkpoint inhibitors (ICIs) has revolutionized cancer
treatment, a high proportion of patients do not respond. Moreover, some types of cancers are …

Abstract Background The TOPAZ-1 phase III trial showed a survival benefit with durvalumab
plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To …

Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy originating from the
epithelial system of the bile ducts, and its incidence in recent years is steadily increasing …

For decades, treatment of advanced biliary tract cancer (BTC) was confined to the use of
chemotherapy. In recent years however, the number of therapeutic options available for …

Simple Summary Cholangiocarcinoma is a relatively rare but deadly disease with
traditionally limited treatment options. The disease can be categorized by anatomic location …

Cholangiocarcinoma (CCA), a rare yet notably aggressive cancer, has experienced a surge
in incidence in recent years. Presently, surgical resection remains the most effective curative …